Navigation Links
Elsevier announces 2008 journal impact factor highlights
Date:6/29/2009

Amsterdam, 29 June 2009 Elsevier, the leading publisher of scientific, technical and medical information products and services, today announced the highlights of its journal impact factor performance in 2008. Elsevier overall saw 75% of its journal impact factors (IF) increase from 2007 to 2008. According to the 2008 Journal Citation Report published by ThomsonReuters, Elsevier journals took the #1 position in 51 categories (of 229 in total) across all of the sciences and social sciences.

In addition, 30 Elsevier journals got their first IF this year. Some of these journals received very impressive scores including two Cell Press journals: Cell Stem Cell (http://www.cell.com/cell-stem-cell/home) (16.826) entered the Cell Biology category ranked 6th (of 157 journals), while Cell Host & Microbe (http://www.cell.com/cell-host-microbe/home) (7.436) entered the Microbiology category ranked10th (of 91 journals). Another impressive result in its first year is Materials Today (http://www.materialstoday.com/) (12.929), which is ranked 4th in the Materials Science, Multidisciplinary category (of 191 journals).

This year there were 182 Elsevier journals that increased their IF by more than 50% over their 2007 scores. All three The Lancet speciality journals improved their IF this year. The Lancet Infectious Diseases (http://www.thelancet.com/journals/laninf/issue/current) increased to 13.165, placing it at the #1 position in the Infectious Diseases category. The Lancet Oncology (http://www.thelancet.com/journals/lanonc/issue/current) rose to 13.283, an increase of over 1 full IF point from the 2007 IF. Finally, The Lancet Neurology (http://www.thelancet.com/journals/laneur/issue/current) increased by 40% to 14.270, thereby retaining the #1 position in the Clinical Neurology category for the 5th year running.

Other Elsevier journals continue their long-running trend of increased IFs, in particular Biomaterials (http://www.elsevier.com/locate/biomaterials) (increasing yearly since 2003) and The Journal of Allergy and Clinical Immunology (http://www.elsevier.com/locate/jaci) which has shown consistent growth over the past five years.

Glen Campbell, Senior Vice President of U.S. Health Sciences Journals said, "Each annual announcement of impact factors confirms the depth and excellence of our health sciences journal publishing program. The superior performance of so many of our journals this year is a sign of the strong partnerships we have with our journal editors and our societies. This year's impact factor growth is one indication of the hard work and focus on quality of these collaborations."

"The fact that Elsevier's overall results are amongst the best in the industry is a true indication of the impact of the increased focus on quality we have placed on our journals in the past three years. The increased impact factors, across the board, are evidence that the research we publish is of the highest quality," remarked Martin Tanke, Managing Director of Science and Technology Journals. "We are grateful for our strong network of editors we partner with, who work with us each day to build our journals to some of the best in their fields."

The impact factor is a measure of the frequency with which the average article in a journal has been cited in a particular year. The impact factor helps to evaluate a journal's relative importance, especially when compared with others in the same field.


'/>"/>

Contact: Shira Tabachnikoff
s.tabachnikoff@elsevier.com
31-204-852-736
Elsevier
Source:Eurekalert

Related biology news :

1. Institution of Chemical Engineers chooses Elsevier as publishing partner
2. Elsevier announces new journal partnership for 2008
3. Elsevier launches new journal: Journal of Natural Gas Science and Engineering
4. Elsevier launches Bioscience Hypotheses
5. Elsevier announces 10 semi-finalists for the Elsevier Grand Challenge
6. Elsevier congratulates its British Medical Association Award winning medical authors and editors
7. Elsevier partners with the Royal Netherlands Society for Agricultural Sciences
8. Elsevier announces winners of 3rd Annual Scopus Young Indian Scientist Award
9. Finalists announced in the Elsevier Grand Challenge
10. Winners announced in the Elsevier Grand Challenge
11. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative ... ... Maldives Immigration ... Algeen (small picture on the right) have received the IAIR award for ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... today announces publication of a United States multicenter, prospective clinical study that ... disposable, point-of-care diagnostic test capable of identifying clinically significant acute bacterial and ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
Breaking Biology Technology: